SCHEMBL20103456

SCHEMBL20103456

Oc1ccc(F)c(C2CCC(O)CC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 4/20 0.50
DYRK1A Q13627 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
THPO P40225 1/20 0.38
CHRNB2 P17787 1/20 0.37
CHRNA4 P43681 1/20 0.37
MAOB P27338 2/20 0.34
DPP4 P27487 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
SCN9A Q15858 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
ESR1 P03372 2/20 0.33
MAOA P21397 1/20 0.33
OPRK1 P41145 1/20 0.33
PDE2A O00408 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29487576 0.83 KDM1A (0.47) ESR2CHRNB2CHRNA4PTGDR2
SCHEMBL22321256 0.83 KDM1A (0.47) ESR2CHRNB2CHRNA4PTGDR2
SCHEMBL22321255 0.83 KDM1A (0.47) ESR2CHRNB2CHRNA4PTGDR2
SCHEMBL24309549 0.81 CYP1A2 (0.55) ESR2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL20103351 0.81 ESR2 (0.54) ESR2CYP3A4CYP2D6CYP2C9CHRNB2
SCHEMBL6437210 0.77 ESR2 (0.53) ESR2DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL3164917 0.77 ESR2 (0.53) ESR2DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL30386925 0.76 CHRNB2 (0.41) ESR2CHRNB2CHRNA4DPP4ESR1
SCHEMBL23054406 0.76 CHRNB2 (0.41) ESR2CHRNB2CHRNA4DPP4ESR1
SCHEMBL21644922 0.76 FFAR1 (0.45) PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018081047-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 WO disclosed